Value of infliximab (Remicade(®)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

Por Baron, Frédéric, Suciu, Stefan, Amadori, Sergio, Muus, Petra, Zwierzina, Heinz, Denzlinger, Claudio, Delforge, Michel, Thyss, Antoine, Selleslag, Dominik, Indrak, Karel, Ossenkoppele, Gert, de Witte, Theo
Publicado em 2012

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic co...

Por Teschendorf Christian, Sieber Markus, Denzlinger Claudio, Bangerter Markus, Mayerle Julia, Vehling-Kaiser Ursula, Kullmann Frank, Stintzing Sebastian, Hinke Axel, von Weikersthal Ludwig, Giessen Clemens, Freiberg-Richter Jens, Schulz Christoph, Modest Dominik, Moosmann Nicolas, Aubele Philipp, Heinemann Volker
Publicado em 2011-08-01

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic co...

Por Giessen, Clemens, von Weikersthal, Ludwig Fischer, Hinke, Axel, Stintzing, Sebastian, Kullmann, Frank, Vehling-Kaiser, Ursula, Mayerle, Julia, Bangerter, Markus, Denzlinger, Claudio, Sieber, Markus, Teschendorf, Christian, Freiberg-Richter, Jens, Schulz, Christoph, Modest, Dominik Paul, Moosmann, Nicolas, Aubele, Philipp, Heinemann, Volker
Publicado em 2011

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final result...

Por Amadori, Sergio, Suciu, Stefan, Jehn, Ulrich, Stasi, Roberto, Thomas, Xavier, Marie, Jean-Pierre, Muus, Petra, Lefrère, Francois, Berneman, Zwi, Fillet, George, Denzlinger, Claudio, Willemze, Roel, Leoni, Pietro, Leone, Giuseppe, Casini, Marco, Ricciuti, Francesco, Vignetti, Marco, Beeldens, Filip, Mandelli, Franco, De Witte, Theo
Publicado em 2005